Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

It’s the height of meeting season! All our most-read stories this month hailed from the news team’s on-site coverage.

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.